Compare · RPID vs WAT
RPID vs WAT
Side-by-side comparison of Rapid Micro Biosystems Inc. (RPID) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RPID and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $35.87B, about 390.4x RPID ($91.9M).
- Over the past year, RPID is down 45.9% and WAT is up 4.1% - WAT leads by 50.0 points.
- RPID has been more active in the news (20 items in the past 4 weeks vs 9 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 10 for RPID).
- Company
- Rapid Micro Biosystems Inc.
- Waters Corporation
- Price
- $1.99+0.00%
- $365.34-2.95%
- Market cap
- $91.9M
- $35.87B
- 1M return
- -20.72%
- +4.48%
- 1Y return
- -45.92%
- +4.05%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1995
- News (4w)
- 20
- 9
- Recent ratings
- 10
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest RPID
- Director Lowenstein Inese was granted 12,787 shares, increasing direct ownership by 22% to 70,687 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 12,787 shares, increasing direct ownership by 15% to 100,687 units (SEC Form 4)
- Director Malloy Kirk was granted 12,787 shares, increasing direct ownership by 27% to 60,687 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Wirtjes Sean M was granted 12,787 shares, increasing direct ownership by 2% to 568,981 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. was granted 12,787 shares, increasing direct ownership by 1% to 1,190,571 units (SEC Form 4)
- SEC Form SD filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Malloy Kirk was granted 19,300 shares, increasing direct ownership by 67% to 47,900 units (SEC Form 4)
- Director Lowenstein Inese was granted 19,300 shares, increasing direct ownership by 50% to 57,900 units (SEC Form 4)
- Director Pei Melinda Litherland was granted 19,300 shares, increasing direct ownership by 28% to 87,900 units (SEC Form 4)
Latest WAT
- Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
- Wolfe Research resumed coverage on Waters with a new price target
- Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
- Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition